SCHEMBL30765715

SCHEMBL30765715

COc1ccc(CNc2cnc(N3CCOCC3)n(CC(=O)NCc3cc4cnccc4n3S(=O)(=O)c3ccccc3)c2=O)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
PDE4B Q07343 1/20 0.40
MAPT P10636 4/20 0.40
KDM4C Q9H3R0 1/20 0.39
MTNR1B P49286 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
TP53 P04637 3/20 0.36
DGAT2 Q96PD7 1/20 0.35
LMNA P02545 2/20 0.35
THRB P10828 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765582 0.87 KDM4C (0.42) MAPTKDM4CMTNR1BALDH1A1KDM4E
SCHEMBL30765865 0.85 NTRK1 (0.37) KDM4CMEN1KMT2ASMN1; SMN2
SCHEMBL30765874 0.82 NTRK1 (0.41) MTNR1BALDH1A1KDM4E
SCHEMBL30765852 0.79 NTRK1 (0.38) MEN1KMT2A
SCHEMBL30765910 0.78 PDE4B (0.48) ATMPDE4BMAPTKDM4CMEN1
SCHEMBL30765520 0.76 NTRK1 (0.41) MAPTMTNR1BALDH1A1KDM4E
SCHEMBL30765999 0.73 PDE4B (0.44) ATMPDE4BMAPTKDM4CMEN1
SCHEMBL30765718 0.71 NTRK1 (0.45) MTNR1BMEN1KMT2A
SCHEMBL30765849 0.69 KDM4C (0.46) MAPTKDM4CALDH1A1KDM4EPOLB
SCHEMBL30765506 0.68 NTRK1 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed